Home Analyst Ratings JMP Securities reiterates Evelo Biosciences Inc. rating to Outperform and sets...

JMP Securities reiterates Evelo Biosciences Inc. [EVLO] rating to Outperform and sets new price target at $27

JMP Securities maintained its Evelo Biosciences Inc. [NASDAQ:EVLO]‎ rating to the equivalent of ‎Outperform but changed the price target ‎to $27, in a research note dated December 30, 2020. That ‎figure represents around a 139.57% ‎premium ‎from where the company’s shares closed on Tuesday. ‎Some ‎new analysts also started their coverage, with JMP Securities’s analysts assigning the shares to ‎‎”a Mkt ‎outperform” rating in a research note to investors issued in late December. Meanwhile, ‎Morgan ‎Stanley had lowered its rating on EVLO to “an Equal-weight” from the earlier “an Overweight”, ‎in a ‎research note produced for clients May 21, 2020. In addition, there was a downgrade from ‎Jefferies on ‎May 12, 2020. The rater changed EVLO from “a Buy” to “a Hold”.

Get the ‎hottest stocks to trade every day before the market opens 100% ‎free. Click here ‎now. 

Is Evelo Biosciences Inc. [NASDAQ:EVLO] a Good Buy Right Now?

It should be noted ‎that ‎EVLO technical indicators for short, intermediate as well as long term progress have placed an ‎overall ‎average of 100% as Buy. The average signal changed from 100% Buy in the last week and ‎compares ‎with 64% Buy in the past month. Data from Evelo Biosciences Inc.’s Trend Spotter indicated ‎that the ‎signals were Weakest. The stock current average is 0.71 million shares in the past 20 days and ‎the short ‎term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was ‎‎0.36 ‎million shares while the medium term average advocated for 100% Buy. The average long-term ‎signal ‎stands at 100% Buy and the 100-day average volume stands at 0.26 million shares.‎‎


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


EVLO Price Performance

On Wall Street, Evelo Biosciences Inc. [NASDAQ:EVLO] ‎finished ‎Tuesday’s session down -8.22% at $11.27. The stock went up to $12.49 at the same session ‎while its ‎lowest single day price was $10.9701. In the last five days, it saw a rise of about 1.99%, ‎Evelo ‎Biosciences Inc. shares gained by almost 177.59% since the beginning of the year. However, the ‎share ‎price has dropped to as low as -9.84% below its one year high. On 12/28/20, the company ‎shares ‎recorded $12.50, the highest single-day price it has got to in the last 52-weeks and a 52-week ‎low was ‎seen on 03/16/20, the same year at $3.01. The company’s shares have inclined by 167.70% in ‎the past ‎year. The 50-day SMA achieved is $6.17 while the 200-day SMA is $4.91. Volume dropped to ‎‎0.26 ‎million from 0.69 million in the previous session.‎‎

EVLO Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing ‎is ‎perceived around 10.66 level, and in case of violation of this particular level, it will cause more drop ‎to ‎‎10.06 level. On the upper level, 13.10 is still the key resistance. The stock may increase to ‎the ‎subsequent resistance at 12.18. The Relative Strength Index (RSI) pinned on the 14-day chart is ‎‎66.95, ‎implying a neutral technical stance while the MACD stands at 1.56, meaning price will increase in ‎the ‎next trading period. Percent R indicator moved to 17.08%, implying bullish price movement. ‎Stochastic ‎‎%K at 87.49% suggest selling the stock.‎‎

What is the short interest in Evelo Biosciences Inc.?

Short interest in the Evelo ‎Biosciences ‎Inc. stock has surged, increasing by 80000.0 shares to total 2.0 million shares on Dec 14, ‎‎2020. The ‎interest had seen shares on Nov 12, 2020 stand at 2.08 million, data from Yahoo Finance ‎shows. The ‎decrease of -4.0% suggests the stock saw some decreased bullish sentiment. The stock’s ‎days to cover ‎‎(short ratio) moved to while the shorted shares account for just 8.16% of the overall ‎float for the ‎stock.‎
‎‎

Get the hottest stocks to trade every day before the ‎market ‎opens 100% ‎free. Click here now. 

Evelo Biosciences Inc.’s Biggest Shareholders: Who Owns Evelo Biosciences ‎Inc. ‎‎[EVLO]?

Filings by Fidelity Management & Research Co showed that the firm now holds a ‎total of ‎‎5,000,985 shares or roughly 10.83% of the outstanding EVLO shares. This means their shares ‎have ‎increased by 449,766 from the 5,000,985 the investor reportedly held in its prior 13-F filing. With ‎the ‎conclusion of the purchase, Credit Suisse Securities updated stake is worth $12,873,145. Details in ‎the ‎latest 13F filings reveal that Credit Suisse Asset Management acquired their 35.03% stake valued ‎at ‎‎$8,245,998. During the last quarter, Credit Suisse Asset ‎Management raised 417,007 of its shares in ‎Evelo Biosciences Inc. while DNCA Finance SA bought ‎‎1,300,000 shares. The BVF Partners LP’s holdings ‎currently number 1,300,000 shares at $14651000.0. ‎According to the firm’s last 13F report, The ‎Vanguard Group, Inc. shares in the company at filing stood ‎at 848,050 shares, roughly $4,350,497.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

James River Group Holdings Ltd. (NASDAQ: JRVR) stock falls during pre-market. Why is it so?

James River Group Holdings Ltd. (NASDAQ: JRVR) stock plunged by 1.67% at last close while the JRVR stock continued decline by 25.74% at last...

Aviat Networks, Inc. (AVNW) Stock Trending Up After Promising Financial Reports for Most Recent Quarter

Aviat Networks, Inc. (AVNW) stock prices were up 3.81% as of market close on May 5th 2021, bringing the price per share up to...

Regional Health Properties, Inc. (RHE) Stock Skyrocketing as Pandemic Regulations Ease Up

Regional Health Properties, Inc. (RHE) stock prices were up a staggering 90.39% during the course of the trading day on May 5th, 2021, bringing...

What Is Getting Alteryx (AYX) Stock To Soar In Premarket Trades?

The shares of Alteryx Inc. (AYX) rose 7.42% to trade at $82.06 in premarket trading at last check. To close Tuesday's trading session at...

Cocrystal Pharma, Inc. (COCP) Stock Skyrocketed Following Promising Updates on Covid-19 Drug Development

Cocrystal Pharma, Inc. (COCP) stock prices were up by a monumental 72.58% as of the market closing on may 4th 2021, bringing the price...

James River Group Holdings Ltd. (NASDAQ: JRVR) stock falls during pre-market. Why is it so?

James River Group Holdings Ltd. (NASDAQ: JRVR) stock plunged by 1.67% at last close while the JRVR stock continued decline by 25.74% at last...

What Caused Nemaura (NMRD) To Rise Today In Premarket Session?

The shares of Nemaura Medical Inc. (NASDAQ: NMRD) were trading 12.12% higher at $12.4 before the bell at last check. Nemaura stock closed the...

Luokung Technology Corp. (LKCO) Stock Surges Amid China-U.S. Economic Tensions

Luokung Technology Corp. (LKCO) stock prices were down by 8.64% as of the market closing on May 5th, 2021, bringing the price per share...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.